SANOFI GENZYME

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
>
No longer registered as of 03 Mar 2018 - Registration as it was on 02 Mar 2017
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

450,000€

Financial year: Jan 2016 - Dec 2016

Lobbyists (Full time equivalent)

1 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    SANOFI GENZYME   (Genzyme)

    EU Transparency Register

    2946627525-90 First registered on 17 Oct 2008

    Goals / Remit

    Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

    Main EU files targeted

    rare disease policies, pharmaceutical dossiers and use of biotechnology in health care

    in particular in the context of and related to:
    - REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products

    - COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
    - EU Net HTA Joint action
    - RD Action Joint Action
    - IMI

    Address

    Head Office
    Kendall Street, 500
    Cambridge MA 02142
    UNITED STATES
    EU Office
    rue de la science 14
    Brussels 1040
    BELGIUM
  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%1
    25%2

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Ms Vinciane Pirard (Sr Director Public Affairs)

    Person with legal responsibility

    Mr David Meeker (Executive Vice President and Head of Sanofi Genzyme)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2016 - Dec 2016

    Lobbying costs for closed financial year

    450,000€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    Expert Group on Rare diseases

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    None

    Other activities

    To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
    To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.

  • Meetings

    Meetings

    None declared

Download this datacard